Evidence map›Paper›PMID 37542532›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

D-ribose-L-cysteine exhibits restorative neurobehavioral functions through modulation of neurochemical activities and inhibition oxido-inflammatory perturbations in rats exposed to polychlorinated biphenyl.

Mega O Oyovwi, Benneth Ben-Azu, Faith Y Falajiki, Oghenetega B Onome, Rume A Rotu, Rotu A Rotu, Abioye A Oyeleke, Godwin P Okwute, Emuesiri G Moke

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Mega O OyovwiDepartment of Human Physiology, Adeleke University, Ede, Osun State, Nigeria.
Benneth Ben-AzuDepartment of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria. pharmben4ever@yahoo.com.
Faith Y FalajikiDepartment of Human Physiology, Adeleke University, Ede, Osun State, Nigeria.
Oghenetega B OnomeDepartment of Physiology, School of Basic Medical Science, Babcock University, Ilishan-Remo, Ogun State, Nigeria.
Rume A RotuDepartment of Physiology, Faculty of Basic Medical Science, College of Health Sciences, University of Ibadan, Ibadan, Oyo State, Nigeria.
Rotu A RotuDepartment of Industrial Safety and Environmental Management, School of Maritime Technology, Burutu, Delta State, Nigeria.
Abioye A OyelekeDepartment of Physiology, Federal University Oye-Ekiti, Oye-Are Road, Oye-Ekiti, Ekiti State, Nigeria.
Godwin P OkwuteDepartment of Physiology, School of Basic Medical Science, Babcock University, Ilishan-Remo, Ogun State, Nigeria.
Emuesiri G MokeDepartment of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.
Adeleke University · NGBabcock University · NGDelta State Polytechnic Ogwashi-Uku · NGDelta State University · NGFederal University Oye Ekiti · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polychlorinated biphenyl (PCB) is potentially harmful environmental toxicant causing cognitive decline with depressive features. PCB-induced behavioral deficits are associated with neurochemical dysfunctions, immune changes, and oxidative stress. This study investigated the neuroprotective effects of D-ribose-L-cysteine (DRLC), a neuroprotective precursor element of glutathione on PCB-induced neurobehavioral impairments. Following the initial 15 days of PCB (2 mg/kg) exposure to rats, DRLC (50 mg/kg) was given orally for an additional 15 days, from days 16 to 30. Animals were assessed for behavioral effect such as changes in locomotion, cognition, and depression. Oxidative/nitrergic stress markers; antioxidant regulatory proteins paraoxonase-1 (PON-1), heme oxygenase-1 (HO-1), nuclear factor erythroid 2-related factor 2 (Nfr2), NADPH oxidase-1 (NOX-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and neuroinflammation (NF-kβ, and TNF-α); and neurochemical metabolizing enzymes (acetylcholinesterase (AChE), monoamine oxidase-A and -B (MAO-A, MAO-B)) were carried out. The PCB-induced decline in locomotion, cognitive performance, and depressive-like features were reversed by DRLC. More specifically, PCB-induced oxidative and nitrergic stress, typified by reduced levels GSH, CAT, and SOD, accompanied by elevated MDA and nitrite were attenuated by DRLC. Additionally, DRLC restored the neuroinflammatory milieu indicated by decreased NF-kβ and TNF-α levels toward normal. Hyperactivities of AChE, MAO-A, MAO-B, PON-1, and NOX-1 levels as well as Nfr2, NQO1, and PON-1 due to PCB exposure were mitigated by DLRC. Our results suggest DRLC as a prospective neurotherapeutic agent against PCB-induced neurobehavioral impairments such as cognitive deficit and depressive-like feature through antioxidative and anti-nitrergic stress, anti-neuroinflammation, inhibition of brain metabolizing enzymes, and normalization of neurochemical homeostasis.

Indexed as

Polychlorinated BiphenylsThiazolidinesAcetylcholinesteraseAnimalsAntioxidantsCysteineGlutathioneMonoamine OxidaseOxidative StressProspective StudiesRatsTumor Necrosis Factor-alpha2-(1',2',3',4'-tetrahydroxybutyl)thiazolidine-4-carboxylic acidAcetylcholinesteraseAntioxidantsCysteineGlutathioneMonoamine OxidasePolychlorinated BiphenylsThiazolidinesTumor Necrosis Factor-alphaAntioxidantCognitive deficitD-ribose-L-cysteineOxidative stressPolychlorinated biphenylReproductive impairment

Identifiers

PMID37542532
OpenAlexW4385607047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.